Hematology

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Podcasts Q&As
Interactive
Polls Quizzes
Events & Education
ASH Annual Meeting

FDA Alerts

FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA Alert
fda
FDA Alert
FDA Approves First Treatment of Agitation in Patients With Alzheimer Dementia
05/15/2023
Jessica Ganga
Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
05/15/2023